This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2022
Presentations
SGN-B6A | Solid Tumors | Abstract #731
A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a Phase 1 study (SGNB6A-001)
SGN-B6A | Preclinical | Abstract #1186
SGN-B6A induces immunogenic cell death as a secondary mechanism of action